Co-Authors
This is a "connection" page, showing publications co-authored by Mark Schmidt and Yihe Daida.
Connection Strength
1.673
-
Mental and physical health status among chronic hepatitis B patients. Qual Life Res. 2020 Jun; 29(6):1567-1577.
Score: 0.178
-
Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Apr 10.
Score: 0.060
-
Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis?C and Cirrhosis. Adv Ther. 2024 Feb; 41(2):744-758.
Score: 0.059
-
Antiviral Treatment and Response are Associated With Lower Risk of Dementia Among Hepatitis C Virus-Infected Patients. Am J Geriatr Psychiatry. 2023 Dec 21.
Score: 0.058
-
Persistent pruritus associated with worse quality of life in patients with chronic hepatitis. Liver Int. 2024 Feb; 44(2):577-588.
Score: 0.058
-
Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat. 2023 09; 30(9):746-755.
Score: 0.057
-
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co-infection and risk of drug-induced liver injury across two large HBV cohorts in the United States. J Viral Hepat. 2023 06; 30(6):512-519.
Score: 0.055
-
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals. J Viral Hepat. 2023 Mar 05.
Score: 0.055
-
Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018). Clin Infect Dis. 2022 Feb 11.
Score: 0.051
-
Incidence of malignancies among patients with chronic hepatitis B in US health care organizations, 2006-2018. J Infect Dis. 2022 Jan 17.
Score: 0.051
-
Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States. J Viral Hepat. 2021 Dec 14.
Score: 0.051
-
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. Dig Dis Sci. 2021 Sep 09.
Score: 0.050
-
The Persistence of Underreporting of Hepatitis C as an Underlying or Contributing Cause of Death, 2011-2017. Clin Infect Dis. 2021 09 07; 73(5):891-894.
Score: 0.050
-
Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016). J Clin Gastroenterol. 2021 Mar 17.
Score: 0.048
-
Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017. J Clin Gastroenterol. 2021 01; 55(1):77-83.
Score: 0.048
-
Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C. Am J Gastroenterol. 2020 Dec 24; Publish Ahead of Print.
Score: 0.047
-
Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure. Hepatol Commun. 2021 03; 5(3):400-411.
Score: 0.047
-
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis. Clin Epidemiol. 2020; 12:1261-1267.
Score: 0.047
-
Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. Am J Gastroenterol. 2020 02; 115(2):262-270.
Score: 0.045
-
Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities. Am J Manag Care. 2019 08; 25(8):369-374.
Score: 0.043
-
Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat. 2019 10; 26(10):1210-1217.
Score: 0.043
-
Trends in Diagnosed Chronic Hepatitis B in a US Health System Population, 2006-2015. Open Forum Infect Dis. 2019 Jul; 6(7):ofz286.
Score: 0.043
-
Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis. 2019 03 05; 68(6):956-963.
Score: 0.042
-
Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 2019 06; 39(6):1027-1032.
Score: 0.042
-
Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019 03; 49(5):599-608.
Score: 0.042
-
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. Infect Dis Clin North Am. 2018 06; 32(2):253-268.
Score: 0.040
-
Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States. Gastroenterology. 2018 02; 154(3):754-758.
Score: 0.039
-
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clin Gastroenterol Hepatol. 2018 Aug; 16(8):1342-1350.e1.
Score: 0.039
-
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. Clin Gastroenterol Hepatol. 2018 Aug; 16(8):1333-1341.e6.
Score: 0.038
-
Changing trends in complications of chronic hepatitis C. Liver Int. 2018 02; 38(2):239-247.
Score: 0.037
-
Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. J Clin Gastroenterol. 2017 Jul 21.
Score: 0.037
-
Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015. J Clin Gastroenterol. 2017 Jun 05.
Score: 0.037
-
Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017 Jun; 32(6):1250-1257.
Score: 0.037